Curated CRC research — accessible, accurate, actionable

The CRC Digest

Friday, July 31, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ▪ SCREENING

  Phase 3 FIND trial shows ctDNA-guided surveillance detects recurrence earlier than standard CT scans after curative surgery

  The randomized trial found that circulating tumor DNA methylation monitoring identified recurrent metastatic disease with a more favorable and potentially resectable anatomical profile, significantly increasing the proportion of patients who received curative-intent metastasis-directed therapy. (Journal of Clinical Oncology)

• ◆ TRIAL DATA

  Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status

  Research shows that patients with deficient mismatch repair or high microsatellite instability can benefit from immunotherapy even when they have poor performance status, a group often excluded from clinical trials. (Clinical Colorectal Cancer)

• ▸ TREATMENT

  Preclinical study shows fruquintinib combined with TAS-102 has antitumor activity in colorectal and gastric cancer models

  Fruquintinib, an oral inhibitor of all three vascular endothelial growth factor receptors that has been approved for chemorefractory CRC, showed combined antitumor activity with TAS-102 in xenograft models. (BMC Cancer)

• ▪ SCREENING

  Gut microbiome signatures show promise for non-invasive detection of colorectal neoplasia

  Multinational metagenomic studies have identified reproducible microbial signatures associated with CRC, offering a potential alternative to current stool-based tests that have limited sensitivity for adenoma detection. (Journal of Gastroenterology)

Stay informed, stay hopeful — research continues to move forward.